<DOC>
	<DOCNO>NCT00450944</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins , anti-CD19 anti-CD22 , find cancer cell express CD19 CD22 kill without harm normal cell . This may effective treatment B-cell acute lymphoblastic leukemia . PURPOSE : This phase I trial study side effect best dose anti-CD19 anti-CD22 immunotoxins treat patient refractory relapse B-cell acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Anti-CD19 Anti-CD22 Immunotoxins Treating Patients With Refractory Relapsed B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose deglycosylated ricin A chain-conjugated anti-CD19 anti-CD22 immunotoxins ( Combotox ) patient refractory relapse B-cell acute lymphoblastic leukemia . - Determine toxicity Combotox patient . - Determine pharmacokinetic ( PK ) profile Combotox patient . - Determine antitumor activity Combotox , term percentage blast bone marrow peripheral blood . - Determine level human antimouse human anti-dgA antibody patient treat Combotox . - Determine correlation PK parameter toxicity Combotox patient . - Determine expression CD19 CD22 cell surface antigens affected Combotox . OUTLINE : This dose-escalation study . Patients receive deglycosylated ricin A chain-conjugated anti-CD19 anti-CD22 immunotoxins ( Combotox ) IV 4 hour day 1 , 3 , 5 absence disease progression unacceptable toxicity . Cohorts patient receive escalate dos Combotox maximum tolerate dose determine . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adult acute lymphoblastic leukemia Bcell lineage Refractory relapse disease base bone marrow/peripheral blood examination , cytogenetic study , polymerase chain reaction amplification Disease refractory conventional therapy therapy higher priority At least 50 % blast ( bone marrow peripheral blood ) express CD19 and/or CD22 flow cytometry PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 2 month Creatinine &lt; 1.5 time normal Bilirubin &lt; 1.5 time normal ALT AST &lt; 2.5 time normal PRIOR CONCURRENT THERAPY : Prior chemotherapy , biologic therapy , and/or radiotherapy allow</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
</DOC>